Abstract

HEPATİT B NEDENİYLE KARACİĞER NAKLİ YAPILAN HASTALARDA NÜKSÜ ETKİLEYEN FAKTÖRLER

Öz

Bu çalışmada, kliniğimizde Hepatit B Virus (HBV) nedeniyle karaciğer nakli yapılan hastalarda nükse etki edebilecek faktörler retrospektif olarak değerlendirildi. Çalışmada HBV nedeniyle karaciğer nakli yapılan hastalar nakil sonrası nüks açısından iki gruba ayrıldı. Bu iki grup arasında nükse etki edebilecek faktörler istatistiksel olarak değerlendirildi. Nisan 2014 ile Nisan 2018 tarihleri arasında merkezimizde 42(24.7) hastaya HBV nedeniyle karaciğer nakli yapıldı. Bu hastaların 5(%11.9)’inde nüks görüldü. Nüks gelişen hastalarda nakil öncesi HBV DNA kopya sayısının istatistiksel olarak anlamlı bir şekilde daha yüksek olduğu saptandı.

Anahtar Kelimeler

• Hepatit B Virus,Karaciğer Nakli,Nüks,Takrolimus,Siklosporin

References

1. 1. Alliance, W.H., (2010). Viral Hepatitis Global Policy. Available from: URL: http://www.worldhepatitisalliance.org/theWHA.aspx).
2. 2. Burra, P., Germani, G., Adam, R., Karam. V., Marzano, A., Lampertico, P., et al., (2013). Liver Transplantation for HBV-Related Cirrhosis in Europe: an ELTR Study on Evolution and Outcomes. J Hepatol, 58:287-296.
3. 3. Zheng, S.S., Wu, J., Liang, T.B., Wang, W.L., Huang, D.S., and Xu, X., (2002). Prophylaxis and Treatment of Hepatitis B Virus Reinfection Following Liver Transplantation. Hepatobiliary Pancreat Dis Int, 1:27-329.
4. 4. Akyildiz, M., Karasu, Z., Zeytunlu, M., Aydin, U., Ozacar, T., and Kilic, M., (2007). Adefovir Dipivoxil Therapy in Liver Transplant Recipients for Recurrence of Hepatitis B Virus İnfection Despite Lamivudine Plus Hepatitis B Immunoglobulin Prophylaxis. J Gastroenterol Hepatol, 22:2130-2134.
5. 5. Cholongitas, E. and Papatheodoridis, G.V., (2013). High Genetic Barrier Nucleos(t)ide Analogue(s) for Prophylaxis From Hepatitis B Virüs Recurrence After Liver Transplantation: A Systematic Review. Am J Transplant, 13:353-362.
6. 6. Cholongitas, E., Vasiliadis, T., Antoniadis, N., Goulis, I., Papanikolaou, V., and Akriviadis, E., (2012). Hepatitis B Prophylaxis Post Liver Transplantation with Newer Nucleos(t)ide Analogues After Hepatitis B Immunoglobulin Discontinuation. Transpl Infect Dis, 14:479-487.
7. 7. Samuel, D., Muller, R., Alexander, G., Fassati, L., Ducot, B., Benhamou, J.P., and Bismuth, H., (1993). Liver Transplantation in European Patients with the Hepatitis B Surface Antigen. N Engl J Med, 329:1842-1847.
8. 8. Shouval, D. and Samuel, D., (2000). Hepatitis B Immune Globulin to Prevent Hepatitis B Virus Graft Reinfection Following Liver Transplantation: A Concise Review. Hepatology, 32:1189-1195.

9. 9. Laryea, M.A. and Watt, K.D., (2012). Immunoprophylaxis Against and Prevention of Recurrent Viral Hepatitis After Liver Transplantation. Liver Transpl, 18:514-523.
10. 10. Markowitz, J.S., Martin, P., Conrad, A.J., Markmann, J.F., Seu, P., Yersiz, H., et al., (1998). Prophylaxis Against Hepatitis B Recurrence Following Liver Transplantation Using Combination Lamivudine and Hepatitis B Immune Globulin. Hepatology 28:585-589.
11. 11. Peng, C.Y., Chien, R.N., and Liaw, Y.F., (2012). Hepatitis B Virus-Related Decompensated Liver Cirrhosis: Benefits of Antiviral Therapy. J Hepatol, 57:442-450.
12. 12. Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I.M., et al., (2013). Regression of Cirrhosis During Treatment with Tenofovir Disoproxil Fumarate for Chronic hepatitis B: a 5-year open-label follow-up study. Lancet, 381:468-475.
13. 13. Fung, J., Chan, S.C., Cheung, C., Yuen, M.F., Chok, K.S., Sharr, W., et al., (2013). Oral Nucleoside/nucleotide Analogs without Hepatitis B Immune Globülin After Liver Transplantation for Hepatitis B. Am J Gastroenterol, 108:942-948
14. 14. Marzano, A., Gaia, S., Ghisetti, V., Carenzi, S., Premoli, A., Debernardi-Venon, W., et al., (2005). Viral Load at the time of Liver Transplantation and Risk of Hepatitis B Virus Recurrence. Liver Transpl, 11:402-409.
15. 15. Rifai, K., Wedemeyer, H., Rosenau, J., Klempnauer, J., Strassburg, C.P., Manns, M.P., et al., (2007). Longer Survival of Liver Transplant Recipients with Hepatitis Virus Coinfections. Clin Transplant, 21:258-264.
16. 16. Roche, B. and Samuel, D., (2012). Liver Transplantation in Delta Virus İnfection. Semin Liver Dis, 32:245-255.
17. 17. Campsen, J., Zimmerman, M., Trotter, J., Hong, J., Freise, C., Brown, R., et al., (2013). Liver Transplantation for Hepatitis B Liver Disease and Concomitant Hepatocellular Carcinoma in the United States with Hepatitis B immunoglobulin and Nucleoside/Nucleotide Analogues. Liver Transpl, 19:1020-1029.
18. 18. Blum, H.E. and Moradpour, D., (2002). Viral Pathogenesis of Hepatocellular Carcinoma. J Gastroenterol Hepatol, 17(Suppl 3):S413-420.
19. 19. Saab, S., Yeganeh, M., Nguyen, K., Durazo, F., Han, S., Yersiz, H., et al., (2009). Recurrence of Hepatocellular Carcinoma and Hepatitis B Reinfection in Hepatitis B Surface Antigen-positive Patients After Liver Transplantation. Liver Transpl, 15:1525-1534.
20. 20. Wong, S.N., Reddy, K.R., Keeffe, E.B., Han, S.H., Gaglio, P.J., Perrillo, R.P., et al., (2007). Comparison of Clinical Outcomes in Chronic Hepatitis B Liver Transplant Candidates with and without Hepatocellular Carcinoma. Liver Transpl, 13:334-342.